/CNW/ - Today, Symetryx Corporation ("Symetryx") announced that it has acquired 20% of the issued and outstanding common stock in Neubase Therapeutics Inc....
/PRNewswire/ - Today, Symetryx Corporation ("Symetryx") announced that it has acquired 20% of the issued and outstanding common stock in Neubase Therapeutics...
Lead myotonic dystrophy type 1 (DM1) candidate continues to show promising preclinical data, including the pharmacokinetics (PK) and biodistribution data...
PITTSBURGH and CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a...
PITTSBURGH and CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a...
Investigational New Drug (IND)-enabling studies continue to generate promising data that support further development of the company’s lead myotonic...
PITTSBURGH and CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology...
A single intravenous dose of NeuBase’s Myotonic Dystrophy Type 1 (DM1) development candidate, NT-0231.F, potently rescues splicing, restores chloride...